Clinical trials: Recurrence Hepatocellular Carcinoma
Liver Cancer
Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00467194
- Testing
- Rapamycin, Bevacizumab
- Where
- 2 sites in Singapore
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Cancer Centre, Singapore
Hepatocellular Carcinoma
A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation
Hepatocellular Carcinoma (HCC) recurrence rate is high among liver transplant patients, while treatment measures are limited. This study plans to recruit 39 subjects with Hepatitis B virus (HBV) related HCC after liver…
- Trial name
- NCT02686372
- Testing
- TCR-T, No intervention and TCR-T (at crossover)
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Lion TCR Pte. Ltd.
Thermoablation, Chronic Liver Disease
Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency Ablation
To date, the majority of studies that have evaluated the efficacy of microwave ablation (MWA) in the treatment of hepatocellular carcinoma (HCC) lesions in cirrhotic patients and compared its efficacy with that of percutaneous…
- Conditions
- Thermoablation, Chronic Liver Disease, Hepatocellular Carcinoma
- Trial name
- Thermoablation (NCT02859753)
- Testing
- Percutaneous Radiofrequency Ablation, Percutaneous Microwave Ablation
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Carcinoma, Hepatocellular
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Primary Objective: To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE. Secondary Objectives: 1. To determine the progression-free survival of TACE vs.
- Trial name
- NCT01327521
- Testing
- CyberKnife, TACE, CT Contrast
- Where
- United States
- Sponsor
- Albert Koong
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Hepatic Neoplasm Malignant Recurrent
Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC
The purpose of this study is to verify the superiority of NIK-333 (Peretinoin) to placebo in inhibiting the recurrence of HCV-positive HCC in patients showing complete cure of the disease, with the recurrence-free survival as the…
- Trial name
- NCT01640808
- Testing
- NIK-333(peretinoin)
- Where
- 66 sites in Japan
- Volunteers
- 616 people
- Sponsor
- Kowa Company, Ltd.
Hepatocellular Carcinoma
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
The study is designed to investigate the effect of adjuvant therapy by Sorafenib, Oxaliplatin and S-1 to prevent the tumor recurrence for hepatocellular carcinoma after liver transplantation
- Trial name
- NCT02129322
- Testing
- Sorafenib, S-1, Oxaliplatin
- Where
- China
- Sponsor
- Zhejiang University
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Hepatocellular Carcinoma
Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
This phase II study is to evaluate the efficacy of the adjuvant immunotherapy after curative-intent ablation for recurrent hepatocarcinoma
- Trial name
- NCT05240404
- Testing
- Toripalimab, Thermal ablation
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Xiangya Hospital of Central South University
Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer.
- Conditions
- Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer
- Trial name
- NCT01502410
- Testing
- sorafenib tosylate, pharmacological study, laboratory biomarker analysis
- Where
- 92 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00006010
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 17 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatocellular Carcinoma
Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation
The purpose of this study is to explore the safety of NK cells from Sibship in patients with recurrent hepatocellular carcinoma after liver transplantation.
- Trial name
- NCT02399735
- Testing
- Low Dose NK cells ×4 times, Normal Dose NK cells ×4 times, Normal Dose NK cells ×8 times
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
No-touch RFA Versus Traditional RFA for Small Hepatocellular Carcinoma
Traditional RFA treatment has been a curable therapy for small hepatocellular carcinoma (diameter≤3cm). This technique ablates the tumor via radio frequency by inserting an electrode needle directly into the tumor.
- Trial name
- NCT02830737
- Testing
- Traditional RFA, No-touch RFA
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Southwest Hospital, China
Hepatocellular Carcinoma
Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer
In this study, we intend to divide the subjects who have been confirmed recurrent HCC into two groups: Group A: treatment with pure surgery or Group B: treatment with pure radio frequency.
- Trial name
- NCT00822562
- Testing
- PRFA or PMCT, surgery
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma, Rapamycin
Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC
To evaluate the clinical effect of rapamycin combined with TACE on early-stage HCC with overexpression of ASPH after radical surgery using randomized controlled study and provide a new anti-recurrence treatment for HCC patients…
- Trial name
- NCT02724332
- Testing
- Rapamycin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Recurrent Hepatocellular Carcinoma
Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion
The purpose of this study is to compare the treatment of recurrent hepatocellular carcinoma with repeat hepatectomy,and transcatheter arterial chemoembolization (TACE) with AFP conversion.
- Trial name
- HCCTACEAFP (NCT02728219)
- Testing
- TACE, Hepatectomy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer
Microscopic residual tumor at the resection margin is a critical risk factor for recurrence in patients undergoing hepatectomy for liver cancer, yet current detection relies solely on postoperative pathological examination of the…
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07704216
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Liver Cancer
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524316
- Testing
- doxorubicin hydrochloride, sunitinib malate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
HCC, Adjuvant Therapy
Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection
This is an open label, multi-center, randomized, controlled phase III study, to evaluate the efficacy and safety of sintilimab plus bevacizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk…
- Conditions
- HCC, Adjuvant Therapy, Immunotherapy
- Trial name
- DaDaLi (NCT04682210)
- Testing
- Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-sen University